Prognostic value of Ki-67 compared to S-Phase fraction in axillary node-negative breast cancer

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 585-592

  Brown, Richard W ^a   Allred, D Craig ^b   Clark, Gary M ^b   Osborne, C Kent ^b   Hilsenbeck, Susan G ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67;

ARTICLE; BREAST CANCER; CELL CYCLE S PHASE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CELL DIVISION; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; PROGNOSIS; S PHASE; SURVIVAL RATE;

EID: 0030010161     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. McGuire, W. L. Adjuvant therapy of node-negative breast cancer. N. Engl. J. Med., 320: 525-527, 1989.
2. Tubiana, M., Pejovic, M. S., Renaud, A., Contesso, G., Chavaudra, N., Gioanni, J., and Malaise, E. P. Kinetic parameters and the course of disease m breast cancer. Cancer (Phila.), 47: 937-943, 1981.
3. Meyer, J. S., and Hixon, B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Res., 39: 4042-4047, 1979.
4. Meyer, J. S., and Lee, J. Y. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res., 40: 1890-1896, 1980.
5. Gentili, C., Sanfilippo, O., and Silvestrini, R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer (Phila.), 48: 974-979, 1981.
6. Meyer, J. S., Friedman, E., McCrate, M. M., and Bauer, W. C. Prediction of early course of breast carcinoma by thymidine labeling. Cancer (Phila.), 51: 1879-1886, 1983.
7. Tubiana, M., Pejovic, M. H., Chavaudra, N., Contesso, G., and Malaise, E. P. The long-term prognostic significance of the thymidine labeling index in breast cancer. Int. J. Cancer, 33: 441-445, 1984.
8. Silvestrini, R., Daidone, M. G., and Gasparini, G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer (Phila.), 56: 1982-1987, 1985.
9. Meyer, J. S., and Coplin, M. D Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors: comparisons and correlations. Am. J. Clin. Pathol., 89: 586-595, 1988.
10. McGuire, W. L. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res. Treat., 10. 5-9, 1987.
11. Sigurdson, H., Baldethorp, B., Borg, A., Dahlberg, M., Fernö, M., Killander, D., and Olsson, H. Indicators of prognosis in node-negative breast cancer. N. Engl. J. Med., 322: 1045-1053, 1990.
12. Hitchcock, C. L. Ki-67 staining as a means to simplify analysis of tumor cell proliferation. Am J Clin. Pathol., 96: 444-446, 1991.
13. Schluter, C., Duchrow, M., Wohlenberg, C., Becker, M. H. G., Key, G., Flad, H-D., and Gerdes, J. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J. Cell Biol., 123: 513-522, 1993.
14. Gerdes, J., Li, L., Schlueter, C., Duchrow, M., Wohlenberg, C., Gerlach, C., Stahmer, I., Kloth, S., Brandt, E., and Flad, H-D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol., 138: 867-873, 1991.
15. Gerdes, J., Schwab, U., Lemke, H., and Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 31: 13-20, 1983.
16. Gerdes, L. Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., and Stein, H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 133: 1710-1715, 1984.
17. Gasparini, G., Boracchi, P., Verderio, P., and Bevilacqua, P. Cell kinetics in human breast cancer comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int. J. Cancer, 57: 822-829, 1994.
18. Kamel, O. W., Franklin, W. A., Ringus, J. C., and Meyer, J. S. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am. J. Pathol., 134: 107-113, 1989.
19. Gerdes, J., Lelle, R. J., Pickartz, H., Heidenreich, W., Schwarting, R., Kurtsiefer, L., Stauch, G., and Stein, H. Growth factors in breast cancers determined in situ with monoclonal antibodies. J. Clin. Pathol., 39: 977-980, 1986.
20. Gerdes, J , Pickartz, H , Brotherton, J., Hammerstein, V., Weitzel, H., and Stein, H. Growth fractions and estrogen receptors in situ with monoclonal antibodies. Am. J. Pathol. 129: 486-492, 1987.
21. Barnard, N. J., Hull, P., Lemoine, N. R., and Kadar, N. Proliferation index in breast carcinoma determined by Ki-67 staining and its relationship to clinical and pathological variables. J. Pathol., 152: 287-295, 1987.
22. Charpin, C., Andrac, L., Vacheret, H., Habib, M. C., Devictor, B., Lavaut, M. N., and Toga, M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki-67) in breast carcinoma sections. Cancer Res., 48: 4368-4374, 1988.
23. Lellé, R. S., Heidenreich, W., Stauch, G., and Gerdes, J. The correlation of growth factors with histologie grading and lymph nodes status in human mammary carcinoma. Cancer (Phila.), 59: 83-88, 1987.
24. McGurrin, J. F., Doria, M. L. Dawson, P. J., Karrison, T., Stein, H. O., and Franklin, W. A. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer (Phila.), 59: 1744-1750, 1987.
25. Raymond, W. A., and Leong, A. S. Y. The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining. J. Pathol., 158: 203-211, 1989.
26. Helin, M. L., Helle, M. J., Helin, H. J., and Isola, J. J. Proliferation activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of breast carcinomas Arch. Pathol. Lab. Med., 113: 854-857, 1989.
27. Vollmer, G., Gerdes, J., and Knuppen, R. Relationship of cytosolic estrogen and progesterone receptor content and the growth fraction in human mammary Cancer Res., 49: 4011-4014, 1989.
28. Wrba, F., Chott, A., Reiner, A., Markis-Ritzinger, E., and Holzner, J H. Ki-67 immunoreactivity in breast carcinomas in relation to transform receptor expression, estrogen receptor status, and morphological criteria: an immunohistochemical study. Pathology, 46: 255-259, 1989.
29. Bacus, S. S., Goldschmidt, R., Chin, D., Moran, G., Weinberg, D., and Bacus, J. W. Biological grading of breast cancer using antibodies to proliferating cells and other markers. Am. J. Pathol., 135: 783-792, 1989.
30. Domagala, W., Lasota, J., Bartkowiak, J., Weber, K., and Osborn, M Vimentin is preferentially expressed in human carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am. J. Pathol., 136: 219-227, 1990.
31. Marchetti, E , Querzoli, P., Marzola, A., Bagni, A., Feretti, S., Fabris, G., and Nenci, I. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody. Mod. Pathol., 3: 31-35, 1990.
32. Isola, J J., Helm, H. J., Helle, M. J., and Kallioniemi, O. Evaluation of cell proliferation m breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometnc analysis, and mitotic count. Cancer (Phila.), 65: 1180-1184, 1990.
33. Silvestrini R. Cell kinetics: prognostic and therapeutic implications in human tumors. Cell Proliferation, 27: 579-596, 1994
34. Bouzubar, N., Walker, K J., Griffiths, K., Ellis, I. O., Elston, C. W., Robertson, J. F. R., Blamey, R. W., and Nicholson, R. I. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br. J. Cancer, 59: 943-947, 1989.
35. Viehl, P., Chevillard, S., Mosseri, V., Donatini, B., and Magdelenat, H. Ki67 index and S-phase fraction in human breast carcinomas: comparison and correlations with prognostic factors. Am. J. Clin. Pathol., 94: 681-686, 1990.
36. Weikel, W., Beck, T., Mitze, M., and Knapstein, P. G. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res. Treat., 18: 149-154, 1991.
37. Veronese, S M., and Gambacorta, M. Detection of Ki-67 proliferation rate in breast cancer: correlation with clinical and pathologic features. Am. J. Clin. Pathol., 95: 30-34, 1991.
38. Gaglia, P., Bernardi, A., Venesio, T., Caldarola, B., Lauro, D., Cappa, A. P. M., Calderini, P., and Liscia, D. S. Cell proliferation of breast cancer evaluated by anti-Brd-U and anti-Ki67 antibodies: its prognostic value on short-term recurrences. Eur. J. Cancer. 29A: 1509-1513, 1993.
39. Railo, M., Nordling, S., von Boguslawsky, K., Leivonen, M., Kyllonen, L., and von Smitten, K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br. J. Cancer, 68: 579-583, 1993.
40. Veronese, S. M., Gambacorta, M., Gottardi, O., Scanzi, F. Ferrari, M., and Larapertico, P. Proliferation index as a prognostic marker in breast cancer. Cancer (Phila.), 71: 3926-3931, 1993.
41. Rudas, M., Gnant, M. F. X., Mittlböck, M., Neumayer, R., Kummer, A., Jakesz, R., Reiner, G., and Reiner, A. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res. Treat., 32: 165-175, 1994.
42. Keshgegian, A. A., and Cnaan, A. Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67, and MIB-1. Am. J. Clin. Pathol., 104: 42-49, 1995.
43. Clark, G. M., Dressler, L. G., Owens, M. A , Pounds, G., Oldaker, T., and McGuire, W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N. Engl. J. Med., 320: 627-633, 1989.
44. Allred, D. C., Clark, G. M., Tandon, A. K., and McGuire, W. L. Immunohistochemistry on histological sections from small (50 mg) samples of pulverized breast cancer. J. Histotech., 16: 117-120, 1993.
45. McGuire, W. L., De La Garza, M., and Chamness, G. C. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res., 37: 637-639, 1977.
46. Powell, B., Garola, R. E., Chamness, G. C., and McGuire, W. L. Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res., 39: 1678-1682, 1979.
47. Dressler, L G., Seamer, L. C., Owens, M. A., Clark, G. M., and McGuire, W. L. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer (Phila.), 61: 420-427, 1988.
48. Hsu, S. M. Immunohistochemistry. Methods Enzymol., 184: 357-363, 1990.
49. Wenger, C. R., Beardslee, S., Owens, M. A., Pounds, G., Oldaker, T., Vendelay, P., Pandian, M. R , Harrington, D., Clark, G M., and McGuire, W. L. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res. Treat., 28: 9-20, 1993.
50. Fleiss, J. L. Statistical Methods for Rates and Proportions, Ed. 2. New York: John Wiley & Sons, 1981.
51. Cox, D. R., and Oakes, D. Analysis of Survival Data. New York: Chapman and Hall, 1984.
52. Hilsenbeck, S. G., Clark, G. M., and McGuire, W. L. Why do so many prognostic factors fail to pan out? Breast Cancer Res. Treat., 22: 197-206, 1992.
53. Hilsenbeck, S. G., and Clark, G. M. Practical p-value adjustment for optimally selected cutpoints. Stat. Med., 15: 103-112, 1996.
54. Therneau, T. M., and Grambsch, P. M. Martingale-based residuals for survival models. Biometrika, 77: 147-160, 1990.
55. Gerdes, J., Becker, M. H. G., and Key. G. Immunohistochemical detection of tumour growth fraction (Ki67 antigen) in formalin fixed and routinely processed tissues. J. Pathol., 168: 85-87, 1992.
56. Maun, F. A., Girlando, S., Palma, P. D., Buffa, G., Perrone, G., Doglioni, C., Kreipe, H., and Barbareschi, M. Ki-67 antibodies (Ki-S5, MIB-1, and Ki-67) in breast carcinomas: a brief quantitative comparison. Appl Immunohistochem., 2: 171-176, 1994.